Empagliflozin provided consistent cardiovascular and renal benefits in patients with heart failure with reduced ejection fraction regardless of ischemic or nonischemic cause (P-interaction=0.15).
RCT
interaction=0.15). The benefit of empagliflozin on HF hospitalization, the renal composite end point, estimated glomerular filtration slope changes, and health status scores were also consistent in both groups without treatment by cause modification. Conclusions Empagliflozin offers cardiovascular and renal benefits in patients with heart failure with reduced ejection fraction regardless of the cause of HF. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT03057977.
Khan et al. (Sat,) conducted a rct in Heart failure with reduced ejection fraction. Empagliflozin was evaluated. Empagliflozin provided consistent cardiovascular and renal benefits in patients with heart failure with reduced ejection fraction regardless of ischemic or nonischemic cause (P-interaction=0.15).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: